Isofol Medical is a clinical‑stage pharmaceutical company focused on unmet needs in oncology. Its lead candidate, Modufolin®, is an endogenous folate‑based biomodulator designed to increase the efficacy and reduce the side effects of antimetabolite chemotherapies. Modufolin® is the key active metabolite of clinically used folate drugs and does not require metabolic activation, potentially benefiting patients irrespective of their capacity to activate folates. The compound is being evaluated in clinical trials targeting colorectal cancer and osteosarcoma, with the company reporting Phase I/II and Phase II studies. Isofol collaborates with Merck Millipore on R&D and has secured a commercial manufacturing collaboration with Recipharm for exclusive production of Modufolin®. Financially, Recipharm Venture Fund has invested SEK 8 million and Isofol reports having raised SEK 45 million during the past eight months.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2014